Ascletis, a US-China pharma, reported that one of its two potential treatments for hepatitis C, ASC08, a direct acting antiviral agent that Ascletis in-licensed from Roche, produced positive results in a Phase II trial. The trial enrolled Taiwanese patients. After 12 weeks of treatment, the SVR12 (sustained viral response) rate observed in genotype 1 non-cirrhotic Taiwanese patients was 94% and 100% in genotype 1b non-cirrhotic Taiwanese patients. Ascletis pointed out that Genotype 1b accounts for 98% of genotype 1 and 57% of all hepatitis C patients in mainland China.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
